John Conibear
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
John Conibear has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Adrian Cook
National Cancer Audit Collaborating Centre, Clinical Effectiveness Unit Royal College of Surgeons of England London UK
2 shared publications - Neal Navani
Lungs for Living, UCL Respiratory, Department of Medicine, University College London, London, UK
2 shared publications - Sarah Cook
London School of Hygiene & Tropical Medicine 5 Department of Health Services Research and Policy, Faculty of Public Health and Policy London, United Kingdom
2 shared publications A. Baker
Radiotherapy Department, Barts Health NHS Trust, London, UK
1 shared publicationA.C. Tree
Urology Unit, The Royal Marsden NHS Foundation Trust, Sutton, UK; Division of Radiotherapy and Imaging, Institute of Cancer Research, Sutton, UK
1 shared publicationAlex Martin
GenesisCare UK, Oxford & London, United Kingdom
1 shared publication
Latest Publications
- 29 July 2026
- Published by Elsevier in Clinical Oncology
- Vol. 58
Curative-Intent Radiotherapy in the Era of Earlier Lung Cancer Diagnosis: Insights from the National Lung Cancer Audit
- 29 July 2026
- Published by Elsevier in Clinical Oncology
- Vol. 58
Curative-Intent Radiotherapy in the Era of Earlier Lung Cancer Diagnosis: Insights from the National Lung Cancer Audit
- Open Access
- 13 July 2026
- Published by Elsevier in SSRN Electronic Journal
Utilisation and variation in multimodality treatment for resected stage II–IIIA non-small cell lung cancer in England: a population-based cohort study
Background Systemic anti-cancer therapy (SACT) combined with surgical resection has become recommended practice for patients with resectable stage II–IIIA non-small cell lung cancer (NSCLC) who can tolerate SACT. This study examined how practice in England has responded to the changing evidence base. Methods We conducted a population-based cohort study using linked cancer registration, Hospital Episode Statistics, and Systemic Anti-Cancer Therapy datasets. The cohort included adults undergoing surgical resection for stage II–IIIA NSCLC between 2018 and 2023. Multimodality treatment was defined as surgery combined with SACT. Multivariable logistic regression was used to identify factors associated with treatment receipt; variation in treatment patterns was assessed by Cancer Alliance. Results Among 11,360 surgically treated patients, 6,103 (53.7%) received multimodality treatment. Most multimodality treatment combined surgery and adjuvant therapy (91.1%); but there was a small shift to greater use of neoadjuvant therapy in 2023. Greater use of multimodality treatment was associated with stage IIIA than stage II disease (65.0% vs 46.6%), younger age, better performance status, and lower frailty. There was persistent variation across Cancer Alliances, with case-mix-adjusted treatment rates ranging from approximately 49% to 61%. Conclusions In England, use of multimodality treatment for resected stage II–IIIA NSCLC has increased but remains incomplete and varies geographically. Treatment delivery was associated with patient fitness, tumour stage, and socioeconomic deprivation, but these factors did not explain regional variation, suggesting opportunities to improve equitable delivery of multimodality care in routine practice.
- 13 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessUtilisation and variation in multimodality treatment for resected stage II–IIIA non-small cell lung cancer in England: a population-based cohort study
Background Systemic anti-cancer therapy (SACT) combined with surgical resection has become recommended practice for patients with resectable stage II–IIIA non-small cell lung cancer (NSCLC) who can tolerate SACT. This study examined how practice in England has responded to the changing evidence base. Methods We conducted a population-based cohort study using linked cancer registration, Hospital Episode Statistics, and Systemic Anti-Cancer Therapy datasets. The cohort included adults undergoing surgical resection for stage II–IIIA NSCLC between 2018 and 2023. Multimodality treatment was defined as surgery combined with SACT. Multivariable logistic regression was used to identify factors associated with treatment receipt; variation in treatment patterns was assessed by Cancer Alliance. Results Among 11,360 surgically treated patients, 6,103 (53.7%) received multimodality treatment. Most multimodality treatment combined surgery and adjuvant therapy (91.1%); but there was a small shift to greater use of neoadjuvant therapy in 2023. Greater use of multimodality treatment was associated with stage IIIA than stage II disease (65.0% vs 46.6%), younger age, better performance status, and lower frailty. There was persistent variation across Cancer Alliances, with case-mix-adjusted treatment rates ranging from approximately 49% to 61%. Conclusions In England, use of multimodality treatment for resected stage II–IIIA NSCLC has increased but remains incomplete and varies geographically. Treatment delivery was associated with patient fitness, tumour stage, and socioeconomic deprivation, but these factors did not explain regional variation, suggesting opportunities to improve equitable delivery of multimodality care in routine practice.
- 27 November 2025
- Published by Elsevier in Clinical Oncology
- Vol. 50, 103990
Establishing a National SABR Service: A Model for Safe and Effective Clinical Implementation
- 27 November 2025
- Published by Elsevier in Clinical Oncology
- Vol. 50, 103990
Establishing a National SABR Service: A Model for Safe and Effective Clinical Implementation
- Open Access
- 23 September 2025
- Published by Elsevier in Advances in Radiation Oncology
- Vol. 10 (12) , 101906
Safety and Efficacy of Stereotactic Magnetic Resonance-Guided Adaptive Radiation Therapy (SMART) for Ultracentral Metastases in Non-Small Cell Lung Cancer
- 23 September 2025
- Published by Elsevier in Advances in Radiation Oncology
- Vol. 10 (12) , 101906
Open AccessSafety and Efficacy of Stereotactic Magnetic Resonance-Guided Adaptive Radiation Therapy (SMART) for Ultracentral Metastases in Non-Small Cell Lung Cancer
- Open Access
Multimodality local consolidative treatment versus conventional care of advanced lung cancer after first-line systemic anti-cancer treatment: study protocol for the RAMON multicentre randomised controlled trial with an internal pilot
Introduction Lung cancer is the most common cause of cancer death worldwide and most patients present with extensive disease. One-year survival is improving but remains low (37%) despite novel systemic anti-cancer treatments forming the current standard of care. Although new therapies improve survival, most patients have residual disease after treatment, and little is known on how best to manage it. Therefore, residual disease management varies across the UK, with some patients receiving only maintenance systemic anti-cancer treatment while others receive local consolidative treatment (LCT), alongside maintenance systemic anti-cancer treatment. LCT can be a combination of surgery, radiotherapy and/or ablation to remove all remaining cancer within the lung and throughout the body. This is intensive, expensive and impacts quality of life, but we do not know if it results in better survival, nor the extent of impact on quality of life and what the cost might be for healthcare providers. The RAMON study (RAdical Management Of Advanced Non-small cell lung cancer) will evaluate the acceptability, effectiveness and cost-effectiveness of LCT versus no LCT after first-line systemic treatment for advanced lung cancer. Methods and analysis RAMON is a pragmatic open multicentre, parallel group, superiority randomised controlled trial. We aim to recruit 244 patients aged 18 years and over with advanced non-small-cell lung cancer from 40 UK NHS hospitals. Participants will be randomised in a 1:1 ratio to receive LCT alongside maintenance treatment, or maintenance treatment alone. LCT will be tailored to each patient’s specific disease sites. Participants will be followed up for a minimum of 2 years. The primary outcome is overall survival from randomisation. Ethics and dissemination The West of Scotland Research Ethics Committee (22/WS/0121) gave ethical approval in August 2022 and the Health Research Authority in September 2022. Participants will provide written informed consent before participating in the study. Findings will be presented at international meetings, in peer-reviewed publications, through patient organisations and notifications to patients. Trial registration number ISRCTN11613852.
Open AccessMultimodality local consolidative treatment versus conventional care of advanced lung cancer after first-line systemic anti-cancer treatment: study protocol for the RAMON multicentre randomised controlled trial with an internal pilot
Introduction Lung cancer is the most common cause of cancer death worldwide and most patients present with extensive disease. One-year survival is improving but remains low (37%) despite novel systemic anti-cancer treatments forming the current standard of care. Although new therapies improve survival, most patients have residual disease after treatment, and little is known on how best to manage it. Therefore, residual disease management varies across the UK, with some patients receiving only maintenance systemic anti-cancer treatment while others receive local consolidative treatment (LCT), alongside maintenance systemic anti-cancer treatment. LCT can be a combination of surgery, radiotherapy and/or ablation to remove all remaining cancer within the lung and throughout the body. This is intensive, expensive and impacts quality of life, but we do not know if it results in better survival, nor the extent of impact on quality of life and what the cost might be for healthcare providers. The RAMON study (RAdical Management Of Advanced Non-small cell lung cancer) will evaluate the acceptability, effectiveness and cost-effectiveness of LCT versus no LCT after first-line systemic treatment for advanced lung cancer. Methods and analysis RAMON is a pragmatic open multicentre, parallel group, superiority randomised controlled trial. We aim to recruit 244 patients aged 18 years and over with advanced non-small-cell lung cancer from 40 UK NHS hospitals. Participants will be randomised in a 1:1 ratio to receive LCT alongside maintenance treatment, or maintenance treatment alone. LCT will be tailored to each patient’s specific disease sites. Participants will be followed up for a minimum of 2 years. The primary outcome is overall survival from randomisation. Ethics and dissemination The West of Scotland Research Ethics Committee (22/WS/0121) gave ethical approval in August 2022 and the Health Research Authority in September 2022. Participants will provide written informed consent before participating in the study. Findings will be presented at international meetings, in peer-reviewed publications, through patient organisations and notifications to patients. Trial registration number ISRCTN11613852.